Denosumab shows promise for GIOP
نویسندگان
چکیده
منابع مشابه
Gene therapy for Parkinson's disease shows promise.
CLINICAL TRIALS NEUROLOGICAL DISEASES ARE AMONG THE MOST INTERESTING APPLICATIONS FOR gene therapy. A er decades of preclinical development, viral vector–based gene transfer has now reached the clinic, and early-stage clinical trials are currently in progress in three areas: congenital blindness and retinal degeneration; the childhood metabolic disorder Bat-ten disease; and the progressive neur...
متن کاملPreliminary breast cancer vaccine study shows promise.
A vaccine designed to treat breast cancer has performed surprisingly well in an initial clinical study. In a phase II trial of 186 patients, the vaccine targeting the HER2/neu E75 peptide reduced the risk of recurrence by 50% in 101 breast cancer patients who were clinically disease free after treatment compared with those who were not treated with the vaccine. Immunized patients also had about...
متن کاملPolypill Shows Promise for Reducing Cardiovascular Disease Risk Factors
Setting and participants. Between March 2007 and August 2008, 2053 individuals aged 45 to 80 years were recruited from 50 centers across India if they had no cardiovascular disease (CVD) but at least 1 of the following CVD risk factors: smoker within past 5 years, type 2 diabetes, blood pressure >140 mm Hg systolic or 90 mm Hg diastolic, abnormal lipid levels (low-density lipoprotein [LDL] chol...
متن کاملTargeting mutant p53 shows promise for sunscreens and skin cancer.
Chronic exposure to UV light is a risk factor for skin cancer in which signature mutations in the p53 tumor suppressor gene occur due to DNA damage and contribute to cancer development. In this issue of the JCI, Tang et al. report on their study of a nonimmunodeficient mouse model of UVB-induced skin cancer and human skin carcinoma cells and show that the mutant p53 conformation-modifying drug ...
متن کاملStool DNA Testing for Colorectal Cancer Shows Promise
Setting and participants. National Institutes of Health– supported trial with industry involvement that included 4482 adults in communities surrounding 22 participating regional and academic health systems in the United States. Participants were asymptomatic, aged 50 to 80 years, and deemed to be at average risk for colorectal cancer. Exclusion criteria included structural colorectal evaluation...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Rheumatology
سال: 2018
ISSN: 1759-4790,1759-4804
DOI: 10.1038/s41584-018-0016-6